Trimtech Therapeutics
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $31.0Mattributed |
|---|---|
| Latest round | seed, $31.0M, 2025-03-15attributed |
| Founded | 2024 |
| Headquarters | Cambridge, UK |
| Industry | bio |
| Stage | seed |
| Website | trimtech.bio |
Trimtech Therapeutics develops targeted protein degraders, branded TRIMTACs and TRIMGLUEs, that selectively remove disease-causing proteins to treat CNS and inflammatory disorders. It is built for patients with intractable disease driven by toxic protein buildup. Its programs use TRIM21, a widely expressed but underused ubiquitin ligase.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-03-15 | seed | $31.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $31.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $31.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | trimtech.bio, read 2026-05-08 |
| Description | self-reported | trimtech.bio, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.